MCID: PNC001
MIFTS: 51

Pancytopenia

Categories: Blood diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Pancytopenia

MalaCards integrated aliases for Pancytopenia:

Name: Pancytopenia 11 28 53 5 43 14 71 75

Classifications:



External Ids:

Disease Ontology 11 DOID:12450
ICD9CM 34 284.1
MeSH 43 D010198
NCIt 49 C34889
SNOMED-CT 68 127034005
UMLS 71 C0030312

Summaries for Pancytopenia

Disease Ontology: 11 An anemia that is characterized by a reduction in the number of red blood cells, white blood cells, and platelets.

MalaCards based summary: Pancytopenia is related to aplastic anemia and hoyeraal hreidarsson syndrome. An important gene associated with Pancytopenia is TCN2 (Transcobalamin 2), and among its related pathways/superpathways are Malignant pleural mesothelioma and Cytokine production by Th17 cells in CF (Mouse model). The drugs Oprelvekin and Nandrolone phenpropionate have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, monocytes and bone, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia: 75 Pancytopenia is a medical condition in which there is significant reduction in the number of almost all... more...

Related Diseases for Pancytopenia

Diseases related to Pancytopenia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 922)
# Related Disease Score Top Affiliating Genes
1 aplastic anemia 32.9 TP53 TERT MPL EPO DKC1 CSF3
2 hoyeraal hreidarsson syndrome 32.5 TERT DKC1
3 amegakaryocytic thrombocytopenia, congenital 32.3 SAMD9 MPL DKC1
4 diamond-blackfan anemia 31.9 TP53 TERT SAMD9L SAMD9 MPL EPO
5 hypersplenism 31.4 FOXP3 EPO CSF3 CSF2
6 myelodysplastic syndrome 31.4 TP53 TERT SAMD9L SAMD9 RUNX1 MPL
7 deficiency anemia 31.3 TTR TPMT TP53 TCN2 MPL FOXP3
8 neutropenia 31.3 TPMT TP53 MPL EPO CSF3 CSF2
9 myelofibrosis 31.2 TP53 RUNX1 MPL EPO CSF3
10 acute leukemia 31.2 TPMT RUNX1 MPL EPO CSF3 CSF2
11 leukemia, acute lymphoblastic 31.1 TPMT TP53 RUNX1 MPL DHFR CSF3
12 thrombocytopenia 31.1 TERT TCN2 SAMD9L RUNX1 MPL FOXP3
13 granulocytopenia 31.1 CSF3 CSF2
14 hemoglobinuria 31.1 MPL EPO CSF3
15 iron metabolism disease 30.9 TTR EPO CP
16 systemic lupus erythematosus 30.9 TPMT TP53 MPL FOXP3 CSF3 CSF2
17 leukemia, acute myeloid 30.8 TP53 TERT SAMD9L RUNX1 MPL FOXP3
18 hematologic cancer 30.8 RUNX1 MPL CSF3 CSF2 CSF1
19 leukemia, chronic myeloid 30.8 TP53 RUNX1 MPL EPO CSF3 CSF2
20 refractory anemia 30.8 MPL EPO CSF3
21 malaria 30.8 TP53 TCN2 FOXP3 EPO DHFR CSF3
22 thrombocytosis 30.7 MPL EPO CSF3 CSF2
23 dyskeratosis congenita 30.7 TP53 TERT SAMD9L SAMD9 MPL ERCC6L2
24 nutritional deficiency disease 30.7 TTR EPO CP
25 aspergillosis 30.6 CSF3 CSF2 CSF1
26 myeloma, multiple 30.6 TP53 EPO CSF3 CSF2 CSF1
27 myeloproliferative neoplasm 30.6 RUNX1 MPL EPO CSF3 CSF2
28 myelophthisic anemia 30.6 MPL EPO
29 childhood acute lymphocytic leukemia 30.5 TPMT RUNX1 DHFR
30 polycythemia vera 30.5 TP53 MPL EPO CSF3 CSF2
31 acute promyelocytic leukemia 30.5 TP53 TERT RUNX1 CSF3 CSF2 CSF1
32 connective tissue disease 30.5 TP53 TERT FOXP3 CSF3 CSF2 CSF1
33 gastroenteritis 30.5 CSF3 CSF2 CP
34 severe combined immunodeficiency 30.4 TP53 FOXP3 DKC1 CSF3 CSF2 CSF1
35 shwachman-diamond syndrome 1 30.4 TP53 TERT SAMD9L SAMD9 ERCC6L2 DNAJC21
36 peripheral nervous system disease 30.3 TTR TP53 TERT FOXP3 EPO CSF3
37 behcet syndrome 30.3 FOXP3 CSF3 CSF2 CP
38 cyclic neutropenia 30.2 CSF3 CSF2 CSF1
39 mirage syndrome 30.2 SAMD9 EPO
40 monocytic leukemia 30.2 RUNX1 CSF3 CSF1
41 ecthyma 30.1 SAMD9L CSF3
42 microscopic polyangiitis 30.1 TERT CSF2
43 splenic sequestration 30.1 MPL EPO
44 arthritis 30.1 TTR FOXP3 CSF2 CSF1 CPT2
45 juvenile myelomonocytic leukemia 30.1 SAMD9L SAMD9 RUNX1 CSF2
46 severe congenital neutropenia 30.1 SAMD9L SAMD9 RUNX1 DNAJC21 CSF3 CSF2
47 essential thrombocythemia 30.1 TP53 TERT MPL EPO CSF3
48 acute megakaryocytic leukemia 30.0 TP53 RUNX1 MPL CSF2
49 blood platelet disease 30.0 TP53 RUNX1 MPL EPO CSF3 CSF2
50 chronic myelomonocytic leukemia 30.0 TP53 RUNX1 MPL CSF3 CSF2 CSF1

Graphical network of the top 20 diseases related to Pancytopenia:



Diseases related to Pancytopenia

Symptoms & Phenotypes for Pancytopenia

MGI Mouse Phenotypes related to Pancytopenia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.28 CP CPT2 CSF1 CSF2 DHFR DKC1
2 immune system MP:0005387 10.2 CP CPT2 CSF1 CSF2 CSF3 DHFR
3 cardiovascular system MP:0005385 10.11 CP CPT2 CSF1 CSF2 DHFR DNAJC21
4 liver/biliary system MP:0005370 10.03 CP CSF1 DHFR EPO FOXP3 RUNX1
5 hematopoietic system MP:0005397 10.03 CP CSF1 CSF2 CSF3 DHFR DKC1
6 respiratory system MP:0005388 9.91 CPT2 CSF1 CSF2 DKC1 EPO FOXP3
7 mortality/aging MP:0010768 9.83 CPT2 CSF1 CSF2 DHFR DKC1 DNAJC21
8 integument MP:0010771 9.28 CSF1 CSF2 CSF3 DHFR DKC1 FOXP3

Drugs & Therapeutics for Pancytopenia

Drugs for Pancytopenia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 83)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oprelvekin Approved, Investigational Phase 4 145941-26-0
2
Nandrolone phenpropionate Approved, Illicit, Investigational Phase 3 62-90-8 229455
3
Nandrolone decanoate Approved, Illicit Phase 3 360-70-3 9677
4
Nandrolone Experimental, Investigational Phase 3 434-22-0 9904
5 Anabolic Agents Phase 3
6 Hormones Phase 3
7 Hormone Antagonists Phase 3
8 Androgens Phase 3
9
Levamisole Approved, Investigational, Vet_approved, Withdrawn Phase 2 14769-73-4 26879
10
Prednisone Approved, Vet_approved Phase 2 53-03-2 5865
11
Prednisolone phosphate Approved, Vet_approved Phase 2 302-25-0
12
Prednisolone acetate Approved, Vet_approved Phase 2 52-21-1
13
Prednisolone Approved, Vet_approved Phase 2 50-24-8 4894 5755
14
Methylprednisolone hemisuccinate Approved Phase 2 2921-57-5 1875
15
Methylprednisolone Approved, Vet_approved Phase 2 83-43-2 4159 6741
16
Alemtuzumab Approved, Investigational Phase 1, Phase 2 216503-57-0
17
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
18
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
19
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
20
Fludarabine Approved Phase 2 75607-67-9, 21679-14-1 30751 657237
21
Mycophenolic acid Approved, Investigational Phase 2 24280-93-1 446541
22
Tacrolimus Approved, Investigational Phase 2 104987-11-3 6473866 445643
23
Busulfan Approved, Investigational Phase 2 55-98-1 2478
24
Hydroxyurea Approved Phase 2 127-07-1 3657
25
Coenzyme M Approved, Investigational Phase 2 3375-50-6 598 23662354
26
Abatacept Approved Phase 1, Phase 2 332348-12-6
27
Levoleucovorin Approved, Experimental, Investigational Phase 2 68538-85-2, 58-05-9, 73951-54-9 149436 6006
28
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 4112 126941
29
Rituximab Approved Phase 1, Phase 2 174722-31-7
30
Melphalan Approved Phase 1, Phase 2 148-82-3 4053 460612
31
Treosulfan Approved, Investigational Phase 2 299-75-2 9296
32
Clofarabine Approved, Investigational Phase 2 123318-82-1 119182
33
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
34
Lenograstim Approved, Investigational Phase 2 135968-09-1
35
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
36
Prednisolone hemisuccinate Experimental Phase 2 2920-86-7 4897
37 Adjuvants, Immunologic Phase 2
38 Anthelmintics Phase 2
39 Antiparasitic Agents Phase 2
40 glucocorticoids Phase 2
41
Methylprednisolone Acetate Phase 2 584547
42 Mitogens Phase 2
43 Antirheumatic Agents Phase 2
44 Anti-Infective Agents Phase 2
45 Calcineurin Inhibitors Phase 2
46 Cyclosporins Phase 2
47 Antifungal Agents Phase 2
48 Antilymphocyte Serum Phase 2
49 Immunosuppressive Agents Phase 2
50 Dermatologic Agents Phase 2

Interventional clinical trials:

(show top 50) (show all 82)
# Name Status NCT ID Phase Drugs
1 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
2 The Impact of Red Cell Age on Product Utilization in the Chronically Transfused Outpatient Population Unknown status NCT02393508 Phase 3
3 Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Selected Non-Malignant Diseases Unknown status NCT01019876 Phase 2, Phase 3 Fludarabine;Cyclophosphamide;Cyclophosphamide 40;Cyclophosphamide 30
4 Multi-Center Trial of Anti-Thymocyte Globulin in Treatment of Aplastic Anemia and Other Hematologic Disorders Completed NCT00000597 Phase 3 antilymphocyte serum;nandrolone
5 Randomized Comparison of Cyclophosphamide Versus Cyclophosphamide Plus Fludarabine In Addition To Anti-Thymocyte Globulin for the Conditioning Therapy in Allogeneic Hematopoietic Cell Transplantation for Bone Marrow Failure Syndrome Completed NCT00774527 Phase 3 Cyclophosphamide-fludarabine-anti thymocyte globulin
6 Bone Marrow Transplantation for Non-Malignant Congenital Bone Marrow Failure Disorders Completed NCT00176878 Phase 2, Phase 3 Fludarabine monophosphate;Busulfan
7 Using Daily Self-administered Indirect Moxibustion to Zusanli St-36 to Reduce Chemotherapy Induced Pancytopenia: a Feasibility Study Unknown status NCT02781155 Phase 1, Phase 2
8 Male Hormones for Telomere Related Diseases Unknown status NCT02055456 Phase 1, Phase 2 Nandrolone Decanoate
9 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
10 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
11 Eltrombopag for Enhancing Platelet Engraftment in Adult Patients Undergoing Cord Blood Transplantation Unknown status NCT01757145 Phase 2 Eltrombopag
12 A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment Completed NCT00065260 Phase 2 Campath-1H;r-ATG;CsA
13 Sirolimus for Patients With Chronic and/or Refractory Autoimmune Cytopenias: A Pilot Series Completed NCT00392951 Phase 1, Phase 2 sirolimus
14 A Randomized Study of Three Immunosuppressive Regimens in Treatment Naive Patients With Severe Aplastic Anemia: Horse ATG/CsA Taper vs Rabbit-ATG/CsA vs Alemtuzumab Completed NCT00260689 Phase 2 Cyclosporine;Alemtuzumab
15 Cyclophosphamide Plus Cyclosporine in Treatment-Naive Severe Aplastic Anemia Completed NCT01193283 Phase 1, Phase 2 Cyclophosphamide;Cyclosporine
16 A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia Completed NCT01187017 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
17 Phase I/II Study of Reduced Intensity Conditioning for Patients With Non-Malignant Diseases Using CD3+/CD19+ Depleted Unrelated Donor or Partially Matched Related Donor Peripheral Stem Cells Completed NCT02277639 Phase 2
18 HLA-HAPLOIDENTICAL FAMILIAL DONOR HEMATOPOIETIC CELL TRANSPLANTATION AFTER REDUCED INTENSITY CONDITIONING OF BUSULFAN, FLUDARABINE, AND ANTI-THYMOCYTE GLOBULIN FOR PATIENTS WITH BONE MARROW FAILURE SYNDROME - A PHASE 2 STUDY Completed NCT00731328 Phase 2
19 Transfusion of CD45RA-depleted Donor Lymphocytes to Improve Regeneration of Antimicrobial Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation Completed NCT02337595 Phase 1, Phase 2
20 CD34+Stem Cell Selection for Patients Receiving Partially Matched Family or Matched Unrelated Adult Donor Allogeneic Stem Cell Transplantations for Malignant and Non-Malignant Disease Completed NCT01049854 Phase 2 Full Intensity with TBI;Full Intensity;Reduced Intensity;Reduced Intensity (Fanconi)
21 Allogeneic Mixed Chimerism Stem Cell Transplantation Utilizing In Vivo and In Vitro Campath for Hemoglobinopathies and Bone Marrow Failure Syndromes Completed NCT00004143 Phase 2 Campath, Chemo and/or TBI Allo SCT
22 A Phase II Trial of Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Completed NCT02224872 Phase 2 Thymoglobulin;Fludarabine;Cyclophosphamide;Mesna;Tacrolimus;Mycophenolic acid mofetil
23 A Phase II Trial of Non-Myeloablative (NMA) Conditioning and Transplantation of Partially HLA-Mismatched/Haploidentical Related or Matched Unrelated Donor (MUD) Bone Marrow for Newly Diagnosed Patients With Severe Aplastic Anemia Completed NCT02833805 Phase 2 Thymoglobulin;Fludarabine;Cyclophosphamide;Tacrolimus;Mycophenolate mofetil
24 Study of TCR Alpha Beta T-Cell and CD19 B-Cell Depletion for Hematopoietic Cell Transplantation From Haploidentical Donors in the Treatment of Non-Malignant Hematological Disorders in Children Recruiting NCT04356469 Phase 2
25 Transplantation of Umbilical Cord Blood From Unrelated Donors in Patients With Hematological Diseases Using a Non-Myeloablative Preparative Regimen Recruiting NCT02722668 Phase 2 Fludarabine;Cyclophosphamide;MMF;Sirolimus
26 Phase II Trial of Reduced Intensity Conditioning Hematopoietic Stem Cell Transplantation for Primary Immune Deficiencies, Immune Dysregulatory Syndromes, and Inherited Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide Recruiting NCT04232085 Phase 2 Alemtuzumab;Fludarabine;Melphalan;Cyclophosphamide;Tacrolimus;Mycophenolate Mofetil
27 Cord Blood Transplantation in Children and Young Adults With Hematologic Malignancies and Non-malignant Disorders Recruiting NCT04644016 Phase 2 Clofarabine;Fludarabine;Busulfan;Cyclosporine-A;Mycophenolate Mofetil
28 A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation Recruiting NCT01962415 Phase 2 Hydroxyurea;Alemtuzumab;Fludarabine;Melphalan;Thiotepa
29 Haploidentical Donor Hematopoietic Cell Transplantation for Patients With Severe Aplastic Anemia Recruiting NCT04558736 Phase 2 Anti-Thymocyte Globulin (Rabbit);Fludarabine;Cyclophosphamide;Mesna;G-CSF
30 Myeloablative Allogeneic Hematopoietic Cell Transplantation Using a Related or Unrelated Donor for the Treatment of Hematological Diseases Recruiting NCT03314974 Phase 2
31 Anti-Viral Central Memory CD8 Veto Cells in Haploidentical Hematopoietic Stem Cell Transplantation Recruiting NCT03622788 Phase 1, Phase 2 Cyclophosphamide;Fludarabine
32 A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders Recruiting NCT03128996 Phase 1, Phase 2 RIC regimen;GVHD prophylaxis regimen
33 Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for the Treatment of Bone Marrow Failure Diseases Recruiting NCT04965597 Phase 2 Treosulfan;Fludarabine Phosphate;Tacrolimus;Methotrexate
34 Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure Recruiting NCT03500731 Phase 1, Phase 2 Rituximab;Alemtuzumab;Fludarabine;Thiotepa;G-CSF;Hydroxyurea
35 Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-Cells Recruiting NCT01174108 Phase 2
36 CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplantation for Non-Malignant Disease Active, not recruiting NCT01966367 Phase 1, Phase 2
37 Clinical Phase II Trial to Compare Treosulfan-based Conditioning Therapy With Busulfan-based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Paediatric Patients With Non-malignant Diseases Active, not recruiting NCT02349906 Phase 2 Treosulfan;Busilvex
38 A UK Multicentre Study of Haploidentical Stem Cell Transplantation in Patients With Haematological Malignancies Active, not recruiting NCT01597219 Phase 2
39 PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders Active, not recruiting NCT03513328 Phase 1, Phase 2 Thiotepa--single daily dose;Thiotepa--escalated dose
40 A Pilot Study of a Thrombopoietin-Receptor Agonist (TPO-R Agonist), Eltrombopag, in Moderate Aplastic Anemia Patients Active, not recruiting NCT01328587 Phase 2 Eltrombopag
41 Phase I/II Pilot Study of Mixed Chimerism to Treat Hemoglobinopathies Suspended NCT01419704 Phase 1, Phase 2
42 Post Transplant CD34+ Selected Stem Cell Infusion to Augment Graft Function in Children With Primary Immunodeficiency Diseases and Bone Marrow Failure Syndromes Terminated NCT01856582 Phase 2
43 A Phase II Study Using the CliniMACS® Device for CD34+ Cell Selection and T Cell Depletion for Graft-versus-Host Disease Prophylaxis in Alternative Donor Stem Cell Transplant Recipients Terminated NCT00968864 Phase 2
44 A Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation Terminated NCT01596699 Phase 2 Alemtuzumab;Busulfan;Fludarabine;Clofarabine
45 Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders Terminated NCT01050439 Phase 2
46 Retroviral Mediated Gene Transfer of the Fanconi Anemia Complementation Group C Gene to Hematopoietic Progenitors of Group C Patients Completed NCT00001399 Phase 1 Transduced CD34+ Cells
47 A Phase I/II Trial of Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF) in Patients Diagnosed With Acquired Aplastic Anemia Completed NCT00001398 Phase 1 Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)
48 A Phase I/II Study to Evaluate the Safety and Tolerability of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure Recruiting NCT04211714 Phase 1
49 Phase I Trial to Evaluate the Safety and Feasibility of CK0801 in Treatment of Bone Marrow Failure Syndrome Active, not recruiting NCT03773393 Phase 1
50 A Study Evaluating BPX-501 T Cells and AP1903 for Prevention of Graft Versus Host Disease (GVHD) After Haploidentical, Related, T Cell-Depleted Hematopoietic Cell Transplantation for Non-Malignant Diseases Active, not recruiting NCT02231710 Phase 1

Search NIH Clinical Center for Pancytopenia

Cochrane evidence based reviews: pancytopenia

Genetic Tests for Pancytopenia

Genetic tests related to Pancytopenia:

# Genetic test Affiliating Genes
1 Pancytopenia 28

Anatomical Context for Pancytopenia

Organs/tissues related to Pancytopenia:

MalaCards : Bone Marrow, Monocytes, Bone, Myeloid, T Cells, Spinal Cord, Lung

Publications for Pancytopenia

Articles related to Pancytopenia:

(show top 50) (show all 7850)
# Title Authors PMID Year
1
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders. 5
31064749 2019
2
Genome instability is a consequence of transcription deficiency in patients with bone marrow failure harboring biallelic ERCC6L2 variants. 5
29987015 2018
3
Perioperative management for a patient with chronic pancytopenia: a case of aplastic anemia with persistent neutropenia following preoperative administration of G-CSF. 53 62
20094735 2010
4
[Intravascular large B-cell lymphoma with pontine involvement successfully treated with R-hyper-CVAD/R-MTX-Ara-C regimen]. 53 62
20379108 2010
5
Massive ascites associated with all-trans retinoic acid treatment in therapy-related acute promyelocytic leukemia. 53 62
20190483 2010
6
Development of thrombopoietin receptor agonists for clinical use. 53 62
19630808 2009
7
Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma--analysis of O6-methylguanine-DNA methyltransferase status. 53 62
19037596 2009
8
Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis. 53 62
18541787 2008
9
Paradoxical elevated thiopurine S-methyltransferase activity after pancytopenia during azathioprine therapy: potential influence of red blood cell age. 53 62
18520612 2008
10
Acute colchicine intoxication in a child: a case report. 53 62
17505274 2007
11
[Asian variant of intravascular large B-cell lymphoma diagnosed by bone marrow biopsy]. 53 62
17313078 2007
12
Donor-type myelodysplastic syndrome with t(2;3) and monosomy 7 after allogeneic peripheral blood stem cell transplantation and liver transplantation in a patient with severe-type aplastic anemia. 53 62
17118765 2006
13
Two cases of thiopurine methyltransferase (TPMT) deficiency--a lucky save and a near miss with azathioprine. 53 62
16995868 2006
14
MPL mutations in 23 patients suffering from congenital amegakaryocytic thrombocytopenia: the type of mutation predicts the course of the disease. 53 62
16470591 2006
15
Thrombopoietin regulates differentiation of rhesus monkey embryonic stem cells to hematopoietic cells. 53 62
15958695 2005
16
[CD5- CD11c+ CD23- small lymphocytic lymphoma evolving from aplastic anemia]. 53 62
15387287 2004
17
[Spontaneous recovery from pancytopenia in a young female patient with paroxysmal nocturnal hemoglobinuria(PNH): changes in the GPI-anchor expression on peripheral blood cells]. 53 62
15103939 2004
18
Refractory chronic GVHD emerging after splenectomy in a marrow transplant recipient with accelerated phase CML. 53 62
12858207 2003
19
Co-administration of Flt-3 ligand counteracts the actions of thrombopoietin in myelosuppressed rhesus monkeys. 53 62
12694260 2003
20
Adult purpura fulminans associated with staphylococcal infection and administration of colony-stimulating factors. 53 62
12609794 2003
21
Safe treatment of thiopurine S-methyltransferase deficient Crohn's disease patients with azathioprine. 53 62
12477776 2003
22
Severe pancytopenia from thiopurine methyltransferase deficiency: a preventable complication of 6-mercaptopurine therapy in children with Crohn disease. 53 62
12454589 2002
23
Azathioprine therapy and adverse drug reactions in patients with inflammatory bowel disease: impact of thiopurine S-methyltransferase polymorphism. 53 62
12172211 2002
24
Girl with combined cellular immunodeficiency, pancytopenia, malformations, deletion 11q23.3 --> qter, and trisomy 8q24.3 --> qter. 53 62
11920839 2002
25
Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. 53 62
11895799 2002
26
[Successful combined therapy with ATG, cyclosporin and G-CSF for both liver dysfunction and bone marrow failure in hepatitis-associated aplastic anemia]. 53 62
11680980 2001
27
Colchicine induced toxicity and pancytopenia at usual doses and treatment with granulocyte colony-stimulating factor. 53 62
11361215 2001
28
Early onset methotrexate-induced pancytopenia and response to G-CSF: a report of two cases. 53 62
17039083 2001
29
c-mpl mutations are the cause of congenital amegakaryocytic thrombocytopenia. 53 62
11133753 2001
30
One novel and two recurrent missense DKC1 mutations in patients with dyskeratosis congenita (DKC). 53 62
11491307 2001
31
Severe 6-thioguanine-induced marrow aplasia in a child with acute lymphoblastic leukemia and inherited thiopurine methyltransferase deficiency. 53 62
11037857 2000
32
[Two cases of intravascular lymphomatosis diagnosed antemortem by transbronchial lung biopsy]. 53 62
10723949 2000
33
Serum thrombopoietin levels in thrombocytopenic and non-thrombocytopenic patients with human immunodeficiency virus (HIV-1) infection. 53 62
10530413 1999
34
Successful cytokine treatment of aplastic anemia following living-related orthotopic liver transplantation for non-A, non-B, non-C hepatitis. 53 62
10081639 1999
35
Recurrent hepatosplenomegaly and peripheral blood cytopenia, persistent Epstein-Barr virus infection and central nervous system manifestation in a patient with lymphadenopathy and low serum uric acid. 53 62
9745782 1998
36
Successful treatment of aplastic anemia with G-CSF and high dose erythropoietin. 53 62
9669693 1998
37
Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. 53 62
9541479 1998
38
T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia. 53 62
9535034 1998
39
Crescentic glomerulonephritis accompanied by myeloperoxidase-antineutrophil cytoplasmic antibodies in a patient having myelodysplastic syndrome with trisomy 7. 53 62
9469507 1998
40
Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells. 53 62
9293906 1997
41
Growth factor administration following autologous peripheral blood progenitor cell transplantation. 53 62
9373197 1997
42
Prevention of thrombocytopenia by thrombopoietin in myelosuppressed rhesus monkeys accompanied by prominent erythropoietic stimulation and iron depletion. 53 62
9207438 1997
43
Copper deficiency with pancytopenia due to enteral nutrition through jejunostomy. 53 62
16844585 1997
44
Treatment of refractory large granular lymphocytic leukemia with 2-chlorodeoxyadenosine. 53 62
9092691 1997
45
Granulocyte-colony stimulating factor in the treatment of colchicine poisoning. 53 62
9154449 1997
46
[Allopurinol induced pancytopenia in a patient with myeloproliferative disorder]. 53 62
9028164 1997
47
Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease. 53 62
8767533 1996
48
Increasing DNA repair methyltransferase levels via bone marrow stem cell transduction rescues mice from the toxic effects of 1,3-bis(2-chloroethyl)-1-nitrosourea, a chemotherapeutic alkylating agent. 53 62
8552605 1996
49
[The Recormon (recombinant erythropoietin) treatment of a patient with pancytopenia of the blood and chronic viral hepatitis C]. 53 62
9019832 1996
50
Combination therapy with recombinant human erythropoietin, interferon-alpha-2b and granulocyte-macrophage colony-stimulating factor in idiopathic myelofibrosis. 53 62
8701705 1996

Variations for Pancytopenia

ClinVar genetic disease variations for Pancytopenia:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 TCN2 NM_000355.4(TCN2):c.428-2A>G SNV Pathogenic
942477 rs2087581122 GRCh37: 22:31010334-31010334
GRCh38: 22:30614347-30614347
2 DNAJC21 NM_001012339.3(DNAJC21):c.544C>T (p.Arg182Ter) SNV Pathogenic
598950 rs771063992 GRCh37: 5:34937536-34937536
GRCh38: 5:34937431-34937431
3 FOXP3 NM_014009.4(FOXP3):c.1190G>A (p.Arg397Gln) SNV Pathogenic
379222 rs1057520529 GRCh37: X:49107901-49107901
GRCh38: X:49251440-49251440
4 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Pathogenic
12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
5 CPT2 NM_000098.3(CPT2):c.149C>A (p.Pro50His) SNV Pathogenic
8954 rs28936375 GRCh37: 1:53662764-53662764
GRCh38: 1:53197092-53197092
6 TTR NM_000371.4(TTR):c.424G>A (p.Val142Ile) SNV Pathogenic
13426 rs76992529 GRCh37: 18:29178618-29178618
GRCh38: 18:31598655-31598655
7 ERCC6L2 NM_020207.7(ERCC6L2):c.3409_3410del (p.Met1137fs) DEL Likely Pathogenic
1174151 GRCh37: 9:98740414-98740415
GRCh38: 9:95978132-95978133
8 RUNX1 NM_001754.5(RUNX1):c.502G>T (p.Gly168Ter) SNV Likely Pathogenic
627081 rs1569078784 GRCh37: 21:36252860-36252860
GRCh38: 21:34880563-34880563
9 ERCC6L2 NM_020207.7(ERCC6L2):c.1973G>A (p.Ser658Asn) SNV Uncertain Significance
1174155 GRCh37: 9:98728869-98728869
GRCh38: 9:95966587-95966587
10 SOX3 NM_005634.3(SOX3):c.735_737dup (p.Ala248dup) DUP Uncertain Significance
95305 rs398124211 GRCh37: X:139586488-139586489
GRCh38: X:140504323-140504324

Expression for Pancytopenia

Search GEO for disease gene expression data for Pancytopenia.

Pathways for Pancytopenia

GO Terms for Pancytopenia

Biological processes related to Pancytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 negative regulation of neuron death GO:1901215 9.63 EPO CSF3 CSF1
2 neutrophil homeostasis GO:0001780 9.56 MPL CSF1
3 negative regulation of miRNA maturation GO:1903799 9.26 TP53 TERT
4 monocyte homeostasis GO:0035702 8.92 MPL CSF1

Molecular functions related to Pancytopenia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 telomerase activity GO:0003720 8.92 TERT DKC1

Sources for Pancytopenia

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....